GlassScriptPhysician profile
Rajinder S Marok
NPI 1740410455
$28,853.93
in general payments reported to CMS, 2019-2025
43 companies · $439 in 2025
The $439 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,410 · 2020: $912 · 2021: $1,860 · 2022: $14K · 2023: $3,158 · 2024: $3,191 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,699 · Travel and Lodging: $1,339 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,699.11 |
| Travel and Lodging | $1,339.17 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $15,657.06 | 2019-2025 | Watchman Flx, Avvigo Guidance System, Watchman Access System |
| Abbott Laboratories | $2,949.26 | 2019-2025 | Navitor, Diamondback Coronary, Amplatzer Amulet |
| Shockwave Medical, INC | $1,318.88 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $1,111.73 | 2022-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $876.48 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $742.50 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $635.23 | 2019-2024 | Andexxa, Farxiga |
| Novartis Pharmaceuticals Corporation | $614.30 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $564.56 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $562.71 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $486.64 | 2019-2021 | |
| Medtronic, INC. | $368.97 | 2022-2023 | Corevalve Evolut R |
| Bayer Healthcare Pharmaceuticals INC. | $367.14 | 2022-2024 | |
| Chiesi USA, INC. | $261.13 | 2020-2024 | Cleviprex, Kengreal |
| Novo Nordisk INC | $252.01 | 2019-2024 | Rybelsus, Ozempic |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajinder Marok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.